TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prospective Randomised Clinical Trial of the Effect of Continuous Versus Intermittent Renal Replacement Therapy on the Mortality and Outcome of Acute Renal Failure in ICU Patients
Brief Summary: The mortality of acute renal failure (ARF) remains to be high (around 60-70%) despite manifold improvements in ICU care. At present, it is not clear if the method chosen for renal replacement therapy, i.e. intermittent haemodialysis (IHD) or continuous haemofiltration (CVVH), might impact on the outcome of these patients. For this purpose, a prospective randomised clinical study of the effect of continuous versus intermittent renal replacement therapy on the mortality and outcome of acute renal failure will be performed.


Options:
A: Arm Label: CVVH using oXiris™ filter; Type: EXPERIMENTAL; Interventions: Biological: Arterial blood sampling, Biological: Ultrafiltrate sampling, Device: CVVH using oXiris™ filter | Arm Label: CVVH using PrismafleX HF1400 filter; Type: ACTIVE_COMPARATOR; Interventions: Biological: Arterial blood sampling, Biological: Ultrafiltrate sampling, Device: CVVH using PrismafleX HF1400 filter | Intervention Type: BIOLOGICAL; Name: Arterial blood sampling; Assigned to Arm(s): CVVH using PrismafleX HF1400 filter, CVVH using oXiris™ filter | Intervention Type: BIOLOGICAL; Name: Ultrafiltrate sampling; Assigned to Arm(s): CVVH using PrismafleX HF1400 filter, CVVH using oXiris™ filter | Intervention Type: DEVICE; Name: CVVH using oXiris™ filter; Assigned to Arm(s): CVVH using oXiris™ filter | Intervention Type: DEVICE; Name: CVVH using PrismafleX HF1400 filter; Assigned to Arm(s): CVVH using PrismafleX HF1400 filter
B: Arm Label: oXiris™ filter; Type: EXPERIMENTAL; Interventions: Device: oXiris™ filter | Arm Label: Toraymyxin Filter; Type: EXPERIMENTAL; Interventions: Device: Toraymyxin Filter | Arm Label: Standard of Care; Type: OTHER; Interventions: Device: Standard of Care | Intervention Type: DEVICE; Name: oXiris™ filter; Assigned to Arm(s): oXiris™ filter | Intervention Type: DEVICE; Name: Toraymyxin Filter; Assigned to Arm(s): Toraymyxin Filter | Intervention Type: DEVICE; Name: Standard of Care; Assigned to Arm(s): Standard of Care
C: Arm Label: CVVH arm; Type: ACTIVE_COMPARATOR; Interventions: Other: RRT for acute kidney failure using the CVVH method | Arm Label: IHD arm; Type: ACTIVE_COMPARATOR; Interventions: Other: RRT for acute kidney failure using the IHD (intermittent HD) | Intervention Type: OTHER; Name: RRT for acute kidney failure using the CVVH method; Assigned to Arm(s): CVVH arm | Intervention Type: OTHER; Name: RRT for acute kidney failure using the IHD (intermittent HD); Assigned to Arm(s): IHD arm
D: Arm Label: CVVHD-ST150; Type: EXPERIMENTAL; Interventions: Other: CVVHD | Arm Label: CVVH-ST150; Type: ACTIVE_COMPARATOR; Interventions: Other: CVVH | Intervention Type: OTHER; Name: CVVHD; Assigned to Arm(s): CVVHD-ST150 | Intervention Type: OTHER; Name: CVVH; Assigned to Arm(s): CVVH-ST150

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparison of Slow Efficiency Daily Dialysis (SLEDD) With Unfractionated Heparin Versus Citrasate in Critically Ill Patients.
Brief Summary: The purpose of this study is to compare the feasibility, safety and efficacy of hemodialysis with unfractionated heparin compared to hemodialysis with Citrasate in Critically Ill Patients.


Options:
A: Arm Label: heparin anticoagulation; Type: ACTIVE_COMPARATOR; Interventions: Drug: Heparin | Arm Label: citrate anticoagulation; Type: EXPERIMENTAL; Interventions: Drug: Citrate | Intervention Type: DRUG; Name: Heparin; Assigned to Arm(s): heparin anticoagulation | Intervention Type: DRUG; Name: Citrate; Assigned to Arm(s): citrate anticoagulation
B: Arm Label: Tunneled dialysis catheter; Type: ACTIVE_COMPARATOR; Interventions: Device: Tunneled versus non-tunneled dialysis catheter insertion | Arm Label: Non-tunneled dialysis catheter; Type: ACTIVE_COMPARATOR; Interventions: Device: Tunneled versus non-tunneled dialysis catheter insertion | Intervention Type: DEVICE; Name: Tunneled versus non-tunneled dialysis catheter insertion; Assigned to Arm(s): Non-tunneled dialysis catheter, Tunneled dialysis catheter
C: Arm Label: Standard Anticoagulation; Type: ACTIVE_COMPARATOR; Interventions: Drug: Unfractionated heparin | Arm Label: Citrasate; Type: EXPERIMENTAL; Interventions: Drug: Citrasate | Intervention Type: DRUG; Name: Unfractionated heparin; Assigned to Arm(s): Standard Anticoagulation | Intervention Type: DRUG; Name: Citrasate; Assigned to Arm(s): Citrasate
D: Arm Label: heparinized saline priming group; Type: EXPERIMENTAL; Interventions: Drug: heparinized saline priming group | Arm Label: nafamostat infusion group after heparinized saline priming; Type: ACTIVE_COMPARATOR; Interventions: Drug: nafamostat infusion after heparinized saline priming | Intervention Type: DRUG; Name: heparinized saline priming group; Assigned to Arm(s): heparinized saline priming group | Intervention Type: DRUG; Name: nafamostat infusion after heparinized saline priming; Assigned to Arm(s): nafamostat infusion group after heparinized saline priming

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparison of Slow Efficiency Daily Dialysis (SLEDD) With Unfractionated Heparin Versus Citrasate in Critically Ill Patients.
Brief Summary: The purpose of this study is to compare the feasibility, safety and efficacy of hemodialysis with unfractionated heparin compared to hemodialysis with Citrasate in Critically Ill Patients.


Options:
A: Arm Label: Nafamostat mesilate group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nafamostat mesilate | Arm Label: No anticoagulation group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Normal saline | Intervention Type: DRUG; Name: Nafamostat mesilate; Assigned to Arm(s): Nafamostat mesilate group | Intervention Type: DRUG; Name: Normal saline; Assigned to Arm(s): No anticoagulation group
B: Arm Label: AKI requring CRRT and use regional citrate anticoagulation; Type: EXPERIMENTAL; Interventions: Procedure: Continuous renal replacement therapy with regional citrate anticoagulation | Arm Label: AKI requring CRRT and not use regional citrate anticoagulation; Type: EXPERIMENTAL; Interventions: Procedure: Continuous renal replacement therapy with no anticoagulation or heparin | Intervention Type: PROCEDURE; Name: Continuous renal replacement therapy with regional citrate anticoagulation; Assigned to Arm(s): AKI requring CRRT and use regional citrate anticoagulation | Intervention Type: PROCEDURE; Name: Continuous renal replacement therapy with no anticoagulation or heparin; Assigned to Arm(s): AKI requring CRRT and not use regional citrate anticoagulation
C: Arm Label: M100; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anticoagulation with nafamostat mesilate | Arm Label: HF1000; Type: EXPERIMENTAL; Interventions: Drug: Anticoagulation with nafamostat mesilate | Intervention Type: DRUG; Name: Anticoagulation with nafamostat mesilate; Assigned to Arm(s): HF1000, M100
D: Arm Label: Standard Anticoagulation; Type: ACTIVE_COMPARATOR; Interventions: Drug: Unfractionated heparin | Arm Label: Citrasate; Type: EXPERIMENTAL; Interventions: Drug: Citrasate | Intervention Type: DRUG; Name: Unfractionated heparin; Assigned to Arm(s): Standard Anticoagulation | Intervention Type: DRUG; Name: Citrasate; Assigned to Arm(s): Citrasate

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparison of Slow Efficiency Daily Dialysis (SLEDD) With Unfractionated Heparin Versus Citrasate in Critically Ill Patients.
Brief Summary: The purpose of this study is to compare the feasibility, safety and efficacy of hemodialysis with unfractionated heparin compared to hemodialysis with Citrasate in Critically Ill Patients.


Options:
A: Arm Label: High citrate group; Type: EXPERIMENTAL; Interventions: Drug: Citrate | Arm Label: Low citrate group; Type: EXPERIMENTAL; Interventions: Drug: Citrate | Intervention Type: DRUG; Name: Citrate; Assigned to Arm(s): High citrate group, Low citrate group
B: Arm Label: PR1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Argatroban | Arm Label: PR2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lepirudin | Intervention Type: DRUG; Name: Argatroban; Assigned to Arm(s): PR1 | Intervention Type: DRUG; Name: Lepirudin; Assigned to Arm(s): PR2
C: Arm Label: Standard Anticoagulation; Type: ACTIVE_COMPARATOR; Interventions: Drug: Unfractionated heparin | Arm Label: Citrasate; Type: EXPERIMENTAL; Interventions: Drug: Citrasate | Intervention Type: DRUG; Name: Unfractionated heparin; Assigned to Arm(s): Standard Anticoagulation | Intervention Type: DRUG; Name: Citrasate; Assigned to Arm(s): Citrasate
D: Arm Label: 1 prostacyclin group; Type: ACTIVE_COMPARATOR; Interventions: Drug: prostacyclin | Arm Label: 2 heparin group; Type: ACTIVE_COMPARATOR; Interventions: Drug: heparin | Intervention Type: DRUG; Name: prostacyclin; Assigned to Arm(s): 1 prostacyclin group | Intervention Type: DRUG; Name: heparin; Assigned to Arm(s): 2 heparin group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multi-vitamins, HAART and HIV/AIDS in Uganda
Brief Summary: The investigators are conducting a double-blind, placebo controlled,randomized trial of multivitamin supplements(containing B-vitamins, C, and E) to determine their efficacy in slowing disease progression, indicated by increased CD4 count, weight gain, and improved quality of life, and decreased morbidity, mortality, and drug-related adverse events (i.e. peripheral neuropathy, anemia, and diarrhea).

The investigators hypothesize that daily multivitamin supplementation will: (1) improve immune reconstitution; (2) improve weight gain, and (3) improve quality of life.


Options:
A: Arm Label: 7000IU/day; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Vitamin D3 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D3; Assigned to Arm(s): 7000IU/day | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Multiple RDA multivitamins; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Multivitamins (including B, C and E) | Arm Label: Single RDA Multivitamins; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Multivitamins B, C and E | Intervention Type: DIETARY_SUPPLEMENT; Name: Multivitamins (including B, C and E); Assigned to Arm(s): Multiple RDA multivitamins | Intervention Type: DIETARY_SUPPLEMENT; Name: Multivitamins B, C and E; Assigned to Arm(s): Single RDA Multivitamins
C: Arm Label: A: Broad spectrum micronutrients; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Micronutrients and antioxidants | Arm Label: B: Identical appearing multivitamins; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Multivitamins and minerals | Intervention Type: DIETARY_SUPPLEMENT; Name: Micronutrients and antioxidants; Assigned to Arm(s): A: Broad spectrum micronutrients | Intervention Type: DIETARY_SUPPLEMENT; Name: Multivitamins and minerals; Assigned to Arm(s): B: Identical appearing multivitamins
D: Arm Label: Multivitamins (B,C,E); Type: EXPERIMENTAL; Interventions: Dietary Supplement: Multivitamin supplements B,C and E | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Multivitamin supplements B,C and E | Intervention Type: DIETARY_SUPPLEMENT; Name: Multivitamin supplements B,C and E; Assigned to Arm(s): Multivitamins (B,C,E), Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of an Active Implementation of a Chronic Disease Management Programme for Patients With Chronic Obstructive Pulmonary Disease (COPD)
Brief Summary: Aims:

To design a proactive implementation strategy for a chronic-disease-management-programme.

To describe effects of the active implementation of a programme for COPD-patients measured on patient-related goals and use of health resources.

To describe stakeholders' evaluation of the implementation.

Materials and method:

An intervention study with 3000 COPD-patients cluster-randomized after a bloc-randomization of their GP-practice. 18 GP-practices in Ringkøbing-Skjern-Municipality are randomized to receive an active implementation or to an "as usual" group. A neighboring municipality acts as "sleeping" control. With data from registers and a questionnaire-survey the effect on COPD-patients self reported-health, evaluation of health system and changes in distribution of health resources is analyzed. How health professionals perceive the implementation and how it influences their conception, interactions and culture is illustrated by interviews with stakeholders.

We expect to see improved health related quality of life, enhanced evaluation of the health system and a more appropriate distribution of health resources in the intervention group.


Options:
A: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Care Coordination | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Care Coordination; Assigned to Arm(s): Intervention
B: Arm Label: Index group; Type: ACTIVE_COMPARATOR; Interventions: Other: Index group | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Index group; Assigned to Arm(s): Index group
C: Arm Label: Intervention; Type: ACTIVE_COMPARATOR; Interventions: Other: Active implementation of a guideline for chronic disease | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: External control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Active implementation of a guideline for chronic disease; Assigned to Arm(s): Intervention
D: Arm Label: Interprofessional Education (IPE); Type: EXPERIMENTAL; Interventions: Other: Interprofessional Education (IPE), Other: Usual care | Intervention Type: OTHER; Name: Interprofessional Education (IPE); Assigned to Arm(s): Interprofessional Education (IPE) | Intervention Type: OTHER; Name: Usual care; Assigned to Arm(s): Interprofessional Education (IPE)

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of the Effectiveness of Vitamin D Supplementation to Pregnant Women and Their Infants in Pakistan
Brief Summary: Vitamin D deficiency is wide spread in South Asian population and is contributing to burden of disease in this region including Pakistan. The relative importance of vitamin D deficiency, mutation in its receptor and maternal and child health has not been established in Pakistan and population based studies are required to explore and avert the maternal and Neonatal complications and consequences of Vitamin D deficiency

The trial will evaluate the effectiveness of Vitamin D supplementation to pregnant women and their Infants. It will be a double blind placebo controlled trial, which will be conducted in a rural district of Pakistan.


Options:
A: Arm Label: Vitamin D supplement; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Vitamin D at 10 ug/day | Arm Label: Vitamin D supplement at 30 ug/day; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Vitamin D at 30 ug/day | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D at 30 ug/day; Assigned to Arm(s): Vitamin D supplement at 30 ug/day | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D at 10 ug/day; Assigned to Arm(s): Vitamin D supplement
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Dietary Supplement: cholecalciferol (vitamin D) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: cholecalciferol (vitamin D); Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): 2
C: Arm Label: Maternal and Neonatal Intervention Arm; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D | Arm Label: Maternal and Neonatal Control Arm; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D; Assigned to Arm(s): Maternal and Neonatal Intervention Arm | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Maternal and Neonatal Control Arm
D: Arm Label: Arm A; Type: N/A; Interventions: Dietary Supplement: 400 IU vitamin D3 | Arm Label: Arm B; Type: N/A; Interventions: Dietary Supplement: 2000 IU vitamin D3 | Intervention Type: DIETARY_SUPPLEMENT; Name: 400 IU vitamin D3; Assigned to Arm(s): Arm A | Intervention Type: DIETARY_SUPPLEMENT; Name: 2000 IU vitamin D3; Assigned to Arm(s): Arm B

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase Ib/II, Multicenter, Randomized, Single-Masked, Sham Injection-Controlled Study of Safety, Tolerability, and Evidence of Activity of FCFD4514S Intravitreal Injections Administered Monthly or Every Other Month to Patients With Geographic Atrophy
Brief Summary: This is a Phase Ib/II, multicenter, randomized, single-masked, sham-injection-controlled study of safety, tolerability, and evidence of activity of FCFD4514S intravitreal injections administered monthly or every other month in patients with geographic atrophy.


Options:
A: Arm Label: FCFD4514S; Type: EXPERIMENTAL; Interventions: Drug: FCFD4514S | Arm Label: sham; Type: SHAM_COMPARATOR; Interventions: Drug: sham | Intervention Type: DRUG; Name: FCFD4514S; Assigned to Arm(s): FCFD4514S | Intervention Type: DRUG; Name: sham; Assigned to Arm(s): sham
B: Intervention Type: PROCEDURE; Name: Subfoveal Choroidal Neovascularization Removal; Assigned to Arm(s): N/A
C: Arm Label: Lampalizumab Once in Every 4 Weeks (Q4W); Type: EXPERIMENTAL; Interventions: Drug: Lampalizumab | Arm Label: Lampalizumab Once in Every 6 Weeks (Q6W); Type: EXPERIMENTAL; Interventions: Drug: Lampalizumab | Arm Label: Sham Comparator; Type: SHAM_COMPARATOR; Interventions: Other: Sham | Intervention Type: DRUG; Name: Lampalizumab; Assigned to Arm(s): Lampalizumab Once in Every 4 Weeks (Q4W), Lampalizumab Once in Every 6 Weeks (Q6W) | Intervention Type: OTHER; Name: Sham; Assigned to Arm(s): Sham Comparator
D: Arm Label: OT-551 antioxidant eye drop; Type: EXPERIMENTAL; Interventions: Drug: OT-551 antioxidant eye drop | Intervention Type: DRUG; Name: OT-551 antioxidant eye drop; Assigned to Arm(s): OT-551 antioxidant eye drop

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prospective, Randomized Clinical Trial of a Silver Eluting Dressing System for Prevention of Lower Extremity Revascularization Wound Complications
Brief Summary: This prospective, multi-institutional randomized clinical trial of a silver ion eluting dressing material compared to standard dry gauze for closed skin incisions after open surgical revascularizations for peripheral vascular occlusive disease. Based on the ability of the silver to lower the bacterial contamination of these vulnerable surgical skin incisions, the investigators hypothesize that immediate application of Acticoat Absorbent® as a post-operative dressing will reduce closed incisional wound complications in patients undergoing lower extremity revascularizations involving infrainguinal skin incisions compared to standard non-silver eluting dressing material.


Options:
A: Arm Label: Silver Eluting Dressing; Type: EXPERIMENTAL; Interventions: Other: Surgical dressing | Arm Label: Standard Guaze; Type: ACTIVE_COMPARATOR; Interventions: Other: Surgical dressing | Intervention Type: OTHER; Name: Surgical dressing; Assigned to Arm(s): Silver Eluting Dressing, Standard Guaze
B: Arm Label: I-ZIP Ocular Bandage; Type: EXPERIMENTAL; Interventions: Device: I-ZIP Ocular Bandage | Arm Label: Oasis 24 hour Soft Shield Collagen Corneal Shield; Type: ACTIVE_COMPARATOR; Interventions: Device: Oasis 24 Hour Soft Shield Collagen Corneal Shield | Intervention Type: DEVICE; Name: I-ZIP Ocular Bandage; Assigned to Arm(s): I-ZIP Ocular Bandage | Intervention Type: DEVICE; Name: Oasis 24 Hour Soft Shield Collagen Corneal Shield; Assigned to Arm(s): Oasis 24 hour Soft Shield Collagen Corneal Shield
C: Arm Label: Control group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Pressure dressing | Arm Label: Experimental group; Type: EXPERIMENTAL; Interventions: Procedure: Normal dressing | Intervention Type: PROCEDURE; Name: Normal dressing; Assigned to Arm(s): Experimental group | Intervention Type: PROCEDURE; Name: Pressure dressing; Assigned to Arm(s): Control group
D: Arm Label: ionic silver-containing dressing; Type: EXPERIMENTAL; Interventions: Procedure: ionic silver-containing dressing | Arm Label: Mupirocin ointment application; Type: EXPERIMENTAL; Interventions: Procedure: Mupirocin ointment application | Arm Label: Conventional dressing; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: ionic silver-containing dressing; Assigned to Arm(s): ionic silver-containing dressing | Intervention Type: PROCEDURE; Name: Mupirocin ointment application; Assigned to Arm(s): Mupirocin ointment application

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Informing Decisions in Chronic Critical Illness: A Randomized Control Trial (RCT)
Brief Summary: The purpose of this study is to test a communication intervention to support family decision-making for patients with chronic critical illness.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Structured information | Arm Label: 2; Type: SHAM_COMPARATOR; Interventions: Other: Unspecific conversation | Intervention Type: BEHAVIORAL; Name: Structured information; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Unspecific conversation; Assigned to Arm(s): 2
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Facilitator-Based intervention | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual Care | Intervention Type: BEHAVIORAL; Name: Facilitator-Based intervention; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Usual Care; Assigned to Arm(s): 2
C: Arm Label: Intensive Communication; Type: EXPERIMENTAL; Interventions: Other: Intensive Communication System | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Intensive Communication System; Assigned to Arm(s): Intensive Communication
D: Arm Label: Supportive Information Team Group; Type: EXPERIMENTAL; Interventions: Behavioral: Supportive Information Team Group | Arm Label: Usual Care Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Supportive Information Team Group; Assigned to Arm(s): Supportive Information Team Group

Answer: D